An Anti-Taz Monoclonal Antibody Recognizing Cell Surface Expressed Taz Protein in Human Tumor Cells Publisher



Ghaffari MH¹ ; Mohammadzadeh M² ; Simonian M¹ ; Hashemi M² ; Sadeghi N³ ; Negahdari B¹ ; Mazloomi M¹ ; Rabbani H³ Show Affiliations
Source: Avicenna Journal of Medical Biotechnology Published:2023

Abstract

Background: WWTR1 or TAZ is a transcriptional co-activator protein expressed in cy-toplasm which functions as the main downstream effector of the Hippo signaling path-way. This pathway is an evolutionally conserved signal cascade, which plays a pivotal role in organ size control and tumorigenesis. Ectopic expression of TAZ has already been observed in many malignancies, while the ectopic localization of TAZ is reported for the first time. The aim of this study was to produce a specific monoclonal antibody (mAb) against a synthetic peptide derived from WWTR1 protein to be used as a research tool in human carcinomas. Methods: A 21-mer synthetic peptide (derived from human TAZ protein) was used for immunization of BALB/c mice after conjugation with Keyhole Limpet Haemocyanin (KLH) using hybridoma technology. The generated mAb reacted with the immunizing peptide employing ELISA assay. The reactivity of the antibody with native TAZ protein was assessed through Western blot, immunocytochemistry, and flow cytometry using different cancer cell lines. Results: The produced mAb could recognize the immunizing peptide in ELISA and Kaff was 0.6×10-9 M. The produced anti-TAZ mAb unlike available commercial anti-TAZ antibody, was capable of specifically recognizing cell surface TAZ in human carcinoma cell lines including MCF-7, Raji, and A431 in Western blot, immunocytochemistry, and flow cytometry assays. As expected, no reactivity was observed using normal Peripheral Blood Mononuclear Cell (PBMC) from healthy donors. Conclusion: Based on the results, TAZ is ectopically expressed on the surface of tumor cell lines which is not the case in normal cells. The generated mAb has a potential to be used as a research tool in studying the expression of TAZ in human carcinomas in different applications. © 2023, Avicenna Journal of Medical Biotechnology. All rights reserved.